| 1 |
34089613 | Hypericin-mediated photodynamic therapy enhances gemcitabine induced Capan-2 cell apoptosis via inhibiting NADPH level. | 2022 Apr 20 |
1 |
| 2 |
33723162 | Hypericin induces apoptosis in K562 cells via downregulation of Myc and Mdm2. | 2021 Jan-Mar |
1 |
| 3 |
33680035 | Hypericin Induces Apoptosis in AGS Cell Line with No Significant Effect on Normal Cells. | 2020 Summer |
1 |
| 4 |
30782173 | Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription. | 2019 Feb 19 |
1 |
| 5 |
31430575 | Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels. | 2019 Dec |
1 |
| 6 |
27302958 | Hypericin, a Naphthodianthrone Derivative, Prevents Methylglyoxal-Induced Human Endothelial Cell Dysfunction. | 2017 Mar 1 |
1 |
| 7 |
27314518 | Anti- and Pro-apoptotic Bcl2 Proteins Distribution and Metabolic Profile in Human Coronary Aorta Endothelial Cells Before and After HypPDT. | 2016 Sep |
1 |
| 8 |
25300800 | Effect of PKCĪ± expression on Bcl-2 phosphorylation and cell death by hypericin. | 2014 Dec |
1 |
| 9 |
23479448 | Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action. | 2013 Jun |
1 |
| 10 |
19932626 | Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. | 2010 Jan 21 |
2 |
| 11 |
12101183 | Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. | 2002 Oct 4 |
2 |
| 12 |
11547546 | Different pathways mediate cytochrome c release after photodynamic therapy with hypericin. | 2001 Aug |
2 |
| 13 |
11724334 | Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin. | 2001 Jul-Aug |
1 |
| 14 |
9329022 | Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. | 1997 Oct |
1 |